pipette
ENEnglish

Implications of the 2026 Cardiovascular-Kidney-Metabolic Syndrome Guideline for GLP-1 Receptor Agonist and SGLT2 Inhibitor Eligibility Among US Adults

D. R. Corsi, C. Wang, Y. M. Kang, A. Zimerman, A. O. Agbaje, F. Moura

PreprintUso en el mundo real

En palabras de los autores

Background The 2026 cardiovascular-kidney-metabolic (CKM) syndrome guideline broadens recommendations for glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), but the increment over pre-2026 standards is unknown. We estimated the number and clinical profile of US adults newly eligible under this guideline. Methods Cross-sectional analysis of adults aged 30-79 years in the 2011-2018 National Health and Nutrition Examination Survey. Adults were newly eligible if they met 2026 CKM guideline indications but not pre-2026 American Diabetes Association, American College of Cardiology/American Heart Association heart failure, Kidney Disease: Improving Global Outcomes, or obesity guideline indications. Sensitivity analyses used 2 US Food and Drug Administration (FDA) label standards. Results Among 175.17 million US adults, 111.84 million (63.8%) were already eligible for either class. The CKM guideline added 7.48 million (95% CI: 6.48 to 8.47), a 6.7% increase, all for GLP-1RA and none for SGLT2i: 6.49 million with overweight (body mass index 27.0-29.9 kg/m2, ethnicity adjusted) and no other cardiometabolic disease, and 0.99 million with type 2 diabetes and 10-year PREVENT cardiovascular risk ?7.5%. Newly eligible adults (86.8% CKM stage 1) were younger (46.2 vs 52.9 years), leaner (27.8 vs 33.0 kg/m2), and at lower 10- and 30-year PREVENT risk (3.6% vs 8.1%; 11.3% vs 19.6%; all P < 0.001). Against FDA labeling, 14.15-25.17 million were newly eligible (7.66-18.20 million for SGLT2i). Assuming a 20% relative risk reduction, the projected number needed to treat per cardiovascular event prevented was 243 over 10 years and 56 over 30 years (ages 30-59) in adults with overweight, versus 61 and 26 in already eligible adults. Conclusions Relative to pre-2026 society guidelines, the 2026 CKM guideline newly confers a GLP-1RA indication on 7.48 million US adults, predominantly at lower cardiovascular risk. Whether treating these adults improves outcomes in a cost-efficient manner remains to be established.

Resultado principalLimitación que admiten los autores

Apareció: martes, 27 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.22.26366274